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ABSTRACT p97 is a cell-surface glycoprotein that is
present in most human melanomas but only in trace amounts
in normal adult tissues. To determine the structure of this
tumor-associated antigen and to identify its functional do-
mains, we have purified and cloned p97 mRNA and determined
its nucleotide sequence. The mRNA encodes a 738-residue
precursor, which contains the previously determined N-termi-
nal amino acid sequence of p97. After removal of a 19-residue
signal peptide, the mature p97 molecule comprises extracellu-
lar domains of 342 and 352 residues and a C-terminal 25-
residue stretch of predominantly uncharged and hydrophobic
amino acids, which we believe acts as a membrane anchor.
Each extracellular domain contains 14 cysteine residues, which
form seven intradomain disulfide bridges, and one or two
potential N-glycosylation sites. Protease digestion studies show
that the three major antigenic determinants of p97 are present
on the N-terminal domain. The domains are strikingly homol-
ogous to each other (46% amino acid sequence homology) and
to the corresponding domains of human serum transferrin
(39% homology). Conservation of disulfide bridges and of
amino acids thought to compose the iron binding pockets
suggests that p97 is also related to transferrin in tertiary
structure and function. We propose that p97 be renamed
melanotransferrin to denote its original identification in mel-
anoma cells and its evolutionary relationship to serotransferrin
and lactotransferrin, the other members of the transferrin
superfamily.
p97 is a tumor-associated antigen that was first identified in
human melanoma by using monoclonal antibodies (1-3). It
has been studied extensively with regard to its expression in
normal and neoplastic tissues and is present in most human
melanomas and in certain fetal tissues, but it is found only in
trace amounts in normal adult tissues (4-6). p97 has been
used as a target for diagnostic imaging of melanomas in
human clinical trials (7).
p97 is a monomeric cell surface sialoglycoprotein, with an
apparent molecular weight as determined by NaDodSO4/
polyacrylamide gel electrophoresis of slightly less than
97,000 (4). Use of monoclonal antibodies has defined three
major antigenic sites, which are present on a stable Mr 40,000
tryptic fragment (4). Subsequent work has shown that at least
two other independently characterized human melanoma-
associated antigens, gp95 (3) and gp87 (8), are identical to
p97.
The N-terminal amino acid sequence of p97 is homologous
to transferrin and, like transferrin, p97 binds iron (9). Anal-
ysis of somatic cell hybrids and by in situ hybridization has
shown that the p97 gene, like the genes for transferrin and the
transferrin receptor, is located on chromosomal region
3q21-3q29 (10, 11). These observations suggest that p97 plays
a role in iron metabolism. To determine the structure of p97
and identify functional and antigenic domains, we have
cloned and sequenced p97 mRNA. The availability of cloned
p97 cDNA will allow us to study the regulation of the
expression of p97 and to develop animal models to study the
usefulness of such tumor-associated antigens in tumor therapy.
METHODS
Polysome Immunopurification. Polysomes prepared from
SK-MEL 28 melanoma cells (12) by magnesium precipitation
(13) were purified by affinity chromatography using three
monoclonal antibodies specific for p97 as described (14).
p97-enriched mRNA was isolated by elution with EDTA and
purified by affinity chromatography on oligo(dT)-cellulose
(Bethesda Research Laboratories).
cDNA Cloning with Oligo(dT) as Primer. For first-strand
cDNA synthesis, p97-enriched mRNA and oligo(dT) (Col-
laborative Research, Waltham, MA) were incubated with
reverse transcriptase (Molecular Genetic Resources). The
second strand was synthesized by incubation with the large
fragment of Escherichia coli DNA polymerase (Bethesda
Research Laboratories), and the double-stranded cDNA was
digested with S1 nuclease (gift from D. Durnam). The cDNA
was then dC-tailed with terminal deoxynucleotidyltransferase
(Bethesda Research Laboratories), hybridized with Pst I-
digested dG-tailed pBR322 (Bethesda Research Laboratories)
(15), and used to transform CaCl2-treated E. coli RR1.
cDNA Cloning with Synthetic Primers. cDNA was prepared
as described above using SK-MEL 28 mRNA and synthetic
oligonucleotide primers. The cDNA was dG-tailed, ligated
with EcoRI-cut XgtlO (16) and an oligonucleotide (AATTC-
CCCCCCCCCCC) bridge, packaged (17), and plated on E.
coli C600 rK- mK+ hfl.
RNA Blot Analysis. SK-MEL 28 mRNA was denatured,
electrophoresed on a 0.7% agarose/2.2 M formaldehyde gel
and transferred to nitrocellulose. The filters were probed with
a nick-translated p973a2fl cDNA insert.
Screening of cDNA Libraries. DNA from colonies of trans-
formed bacteria was bound to paper (18) and screened by
differential hybridization with cDNA probes synthesized on
p97-enriched and unenriched mRNA templates. Libraries in
XgtlO were screened for p97 inserts by plaque hybridization
(19) with genomic exon fragments as probes. Probes were
radiolabeled with [32P]TTP (New England Nuclear; 3200
Ci/mmol; 1 Ci = 37 GBq) by nick-translation to a specific
activity of 5-10 x 101 cpm/,ug.
DNA Sequence Analysis. cDNA inserts were excised and
subcloned into the plasmid vector pEMBL18+ (20) for
subsequent propagation and restriction mapping. cDNA was
also subcloned into the M13mpl8 phage cloning vector (21)
and sequenced using the dideoxy chain-termination method
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FIG. 1. Cell-free translation
_MW of p97 mRNA. Five nanograms
of mRNA was translated in the
reticulocyte lysate system, and
the translation products were
analyzed by NaDodSO4/PAGE
and autoradiography. (A) Total
translation products (0.5 p1), 6-
day exposure. (B) Translation
products (5 ul) immunoprecipi-
tated with anti-p97 serum, 1-day
exposure. Lanes: 1, p97-en-
riched mRNA; 2, unenriched
mRNA.
of Sanger et al. (22). M13 clones containing large inserts were
sequenced by generating deletions using DNase I (23) or
exonuclease III (24) and by using synthetic 21-mer oligonu-
cleotide primers.
RESULTS AND DISCUSSION
Purification of p97 mRNA. Polysomes bearing p97 nascent
chains were purified by incubation with three IgG2a mono-
clonal antibodies (96.5, 118.1, 133.2) specific for distinct
epitopes of p97 (2, 4, 5, 10) followed by affinity chromatog-
raphy on protein A-Sepharose. In a typical experiment, 150
A260 units of polysomes yielded 260 ng of p97-enriched
mRNA, 0.23% of the total mRNA. When translated in
Xenopus oocytes (25) and assayed for p97 as described (5,
10), p97-enriched mRNA yielded 80 pg of p97/ng ofmRNA,
whereas p97-unenriched mRNA yielded only 0.44 pg of
p97/ng ofmRNA, showing that p97 mRNA activity had been
enriched 180-fold. The yield of p97 mRNA activity was 42%.
Translation in the reticulocyte lysate system (26) showed that
p97-enriched mRNA coded for a major polypeptide with an
apparent Mr by NaDodSO4/PAGE of 84,000, which was not
detectable in the translation products of unenriched mRNA,
and was immunoprecipitated by antiserum specific for p97
(Fig. 1). We concluded that it was the unglycosylated
precursor of p97.
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Isolation of cDNA Clones for Human p97. p97-enriched
mRNA was used as template for oligo(dT)-primed cDNA
synthesis. The cDNA was cloned in pBR322, and the result-
ing library was screened with cDNA probes. A 243-base-pair
clone, p973a2fl, was identified that hybridized to p97-
enriched cDNA but not detectably to unenriched cDNA and,
in addition, selected p97 mRNA in hybrid-selection transla-
tion experiments (data not shown). A polyadenylylation
signal (AATAA) and a poly(A) tract were present at the 3' end
of the cDNA. Nick-translated p973a2f1 hybridized 100-fold
more strongly to p97-enriched mRNA than to unenriched
melanoma mRNA and not detectably to fibroblast mRNA
(data not shown). RNA blot analysis with the cloned cDNA
as a probe identified an mRNA of approximately 4 kilobases
that was present in SK-MEL 28 melanoma cells and absent
from fibroblasts (data not shown).
Attempts to obtain cDNA clones extending more than 1
kilobase from the polyadenylylation site were unsuccessful,
possibly due to a region of high G+C content (>80%6) with
extensive secondary structure. Genomic cloning was used to
circumvent this problem. Four overlapping genomic clones
were isolated from libraries of X L47.1 containing size-
fractionated SK-MEL 28 DNA enriched for a specific p97
restriction fragment (unpublished data). Restriction frag-
ments that hybridized to the 4-kilobase p97 mRNA on RNA
blots were sequenced and p97 exons were identified by a
computer-assisted homology search between the predicted
coding sequences and the amino acid sequence ofhuman and
chicken transferrin (11, 27, 28). Three synthetic oligonucle-
otides based on p97 genomic exon sequences were used to
prime cDNA synthesis on SK-MEL 28 mRNA and the cDNA
was cloned into XgtlO. Three overlapping cDNA clones
(lOal, lji, 2fl) spanning 2368 nucleotides of the p97 mRNA,
including the entire coding region, were identified by using
p97 exon-specific fragments as probes (Fig. 2).
Structure of p97. The p97 cDNA sequence is shown in Fig.
3. An open reading frame of 2214 nucleotides extends from
the first ATG, around which the sequence conforms with the
consensus initiation sequence determined by Kozak (29), to
the TGA at position 2215. The most 5' cDNA clone contains
an additional 60 nucleotides upstream of the initiating ATG.
The 3' noncoding region of p97 mRNA, which was not
obtained as a cDNA clone, was identified as a single genomic
exon containing 1667 nucleotides (unpublished data). Resi-
dues 20-32 ofthe predicted amino acid sequence are identical
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FIG. 2. Structure of p97
mRNA. The p97 cDNA clone
p973a2fl was isolated from an
oligo(dT)-primed p97-enriched
melanoma cDNA library in pBR-
322, whereas cDNA clones p972fl,
p971jl,andp9710alwereisolatedby
priming with p97 exon-specific
oligonucleotides and cloned in
XgtlO. The structure of the coding
and noncoding regions of the
mRNA are indicated as is the du-
plicated domain structure ofthe p97
precursor. kb, Kilobase(s).
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ATC CCC CCt CCC ACC CCC CCt CTC TCC CTC
Nt? Arg Cly Pro Ser Cly Ala Lou Trp Lcu
CCA GAG CAC CAC AAC tCC CCC AAC ATC ACC
Pro ClI ClG lte Lye Cys Cly Ass Not Ser
CAC CAC tCC CtC CAC CtC ATC CCC CCC CAC
Asp lie Cys Vat CIs Lou Ite Ala Ala Cl.
CtC AAC CCC CtC CtC CCC CAA CtC TAC CAT
Lou Lye Pro Vatl Vat Cly Clu Val Tyr Asp
ATT CAC ACC CTC AAA CCC CtC AAC tCC TCC
Ile Aop Thr Lou Lye Cly Vat Ly Ser Cys
CCC CCC CTC TCG CC ATC CCC tCC CAT CTA
Cly Arg Leu Ser Vat Not Cly Cys Asp Vat
TAC tCt CAC tCC CTC tCt CCC CTC TCC ACC
Tyr Ser CIi Ser Los Cys Arg Lou Cys Arg
AGC CCC CCC TTC CCC tCC CTC CCC CAA CCC
Ser Cly Ala Phe Arg Cys Lou Ala CIs Cly
CTT CCC TCC TCC CCC CAC CCC CTC CTC TCA
Lou Pro Sr Trp Cly CIs Ala Lou Lou Ser
tCC CAT CtC CCC CCC CTC CCt CCt CAC CCC
Cys lis Lou Ala Arg Vat Pro Ala His Ala
CCt CtC TTC ACC CAC CAC CCC ACC ACC TTC
Arg Lou Pe Scr lie Clu Cly Ser Ser Ph.
CGC CTT CtC CCC ATC CCC ACA CAC ACC TAT
ClI Lou Val Pro Ite Ala Thr CGa Thr Tyr
CCC CTC CCC CCC TAC CTC CCC tCC TCt CtC
Arg Lou Pro Pro Tyr Lou Arg Trp Cys Vat
CTC AAC CCA CAC ATC CAC TCC CtC TCA CCC
Lou Lye Pro CGl Ite CIs Cys Vat Ser Ala
ACT CCC CAC CAC ATT TAC ACC CCC CCC AAC
Ser Cly Cli Asp Ite Tyr Thr Ala Cly Lye
TAC TAC CTC CTC CCC CtC CtC ACA CCC CAC
Tyr Tyr Vat Vat Ala Val Vol Arg Arg Asp
CCC ACC CCt CCA CCC TCC CGA CTC CCC CTC
Cly Ser Pro Ala Cty Trp Asp Val Pro Vat
ACC GAG TTC TtC AAT CCC ACC TCC CtC CCC
er ClIi Phe Phe Ass Ala Ser Cys Val Pro
CCC CCC AAC AAC TCT CtC CCC AAC ACC CAC
Cly Arg Ass Lys Cys Vat Cly Ass Ser Clo
CCC TTC CtC ACC CAC ACA ACC CTC TTT CAC
Ala Phe Vat Arg lie Tbr Thr Vat Phe Asp
CTC CTC TCC CCC AAC CCC cCC CcA CCC CAC
Lou Lou Cys Pro Ass CLy Ala Arg Ala ClI
CCC CAC ACC AAC ATC TTC ACC CTC TAT CCA
Pro Asp Tbr Ass Ie Ph. Tbr Val Tyr Cly
TTC CAC TCC tCC AAC TAT CAT CCC CAA CAC
Ph. A Sepr Scr Ass Tyr Hie Cly Cln Asp
GCC TCC CTC CCC CTC CAC TAC CtC CCC CCC
Cly Trp Lou Cly Leu Asp Tyr Val Ala Ala
CtC CTC CCC CTC CTC CTC CCC CCC CTC CCC
Leu Lou Pro Lou Lou Lou Pro Ala Lou Ala
CCC CCCCCA CTT TCC CCC CCC CCC TCT CCC
CAC CAT TCC TTC CTt TTT TCA AAA CCC ACT
TCA ACC TCT CCC CTC CC? CCC TCC ACT CTA
ATC TTC CtT CCT tTC A AAT AAA CCC AAA
GCC CAC tTC CTC CCA CCC CCA CCC ACC CCC
CTC CTC CCT CTC CCC ACC CTC CTC CCA CCC
Lou Lou Ala Lou Arg Thr Vat Lou Cly Cly
GAG GCC TTC CGC CAA GCG CCC ATC CAC CCC
CGl Ala Phe Arg Clu Ala Cly IIo CGI Pro
GAG CCS CAC CCC ATC ACT CTC CAT CCA CCA
CGL Ala Asp Al& Ita Thr Lou Asp Cly Cly
CAA GAG CTC CCT ACC TCC TAT TAC CCC GCT
Clo Clu Val Cly Tbr Ser Tyr Tyr Ala Val
CAC ACC CCC ATC AAT CCC ACA CTC CCC TGC
His Thr Cly Ite Asa Arg Thr Vat Cly Trp
CTC AAA CCT CTC AGC CAC TAT TTT CCC CCC
Lou Lys Ala Val Ser Asp Tyr Ph* Cly Cly
CCT CAC ACC TCT CCC CAA CCC CTC TCT CAC
Cly Asp Ier Ser Cly Clu Cly Vat Cy$ Asp
CCA CCC CAC CTC CC? Ttt CTC AAC CAC ACC
Ala Cly Asp Val Ala Ph. Vat Lys lie Ser
CAC CAC TtC GAG C?C CTC tCC CCC CAT CCT
Ctn Asp Phe Clu Lau Lou Cys Arg Asp CGy
CTC CTC CTC CCC CCC CAC ACA CAT CCC CCC
Vat Vat Val Arg Ala Asp Thr Asp Cly Cly
CAC ATC TTC ACC TCT CAC CCC TAT CCC CAC
Clo Net Phe Ser Ser Clu Ala Tyr Cly Cl.
CAC CCC TCC CC CCGC CA? CAG TAC CtC CAC
Clu Ala Trp Lou Cly Nis CGl Tyr Lou H1i
CTC TCC ACT CCC CAC ATC CAC AAC TCT CCA
Lcu Ser Thr Pro Clu I1c ClG Lye Cys Cly
AAC TCC CCC CAA CAC TCC ATC CAC CCC ATC
Lys Ser Pro Clo His Cys Net Clu Arg Ie
AAC TAC CCC CtC CT CCC CCA CCC CCC GAG
Lye Tyr Cly Lou Val Pro Ala Ala Cly CGl
ACC TCC CAC CCC TTC ACC TTC CAT GAG CTT
Ser Ser Nis Ala Phe Tbr Lou Asp Clu Law
CCt CCC Ctt ATT CAC ACA CCC TtC ATC CCC
Cly Ala Lou Ite Clo Arg Cly Pbe Ite Arg
CTC AAC AAC CCC AAC AAC TAC CCC TCC TCC
Vat Ass As. Pro Lys Ass Tyr Pro Ser Ser
CAC CCC TAT TAC CCC TAC CCC CCC CCC TTC
Clu Arg Tyr Tyr Cly Tyr Arg Cly Ala Phe
AAC ACA AAC CCC CAC AAT tCC CAC CCC TCC
Ass Thr Asa Cly lie As Ser Clu Pro Trp
CTC TCC CAC TTT CCA CCC TCC AAC CTC CCA
Vat Ser Clo Pbs Ala Ala Cys Ass Lew Ala
CTC CTC CAC AAC CCC CAC CAC CTC TTT CCA
Lou Lou Asp Lye Ala Cl. Asp Lou Pbe Cly
CTC CTT TTC AAC CAT CCC ACC CtC CCC CCC
Leu Lcu Pbs Lye Asp Ala thr Val Arg Ala
CTC CAA CCC ATC TCC TCT CAC CAC tCC TCC
Lou Clu Cly Hot Ser icr Cln ClG Cy Ser
CCC CCC CTC CTC CCC CCC CCC CTC TCA CCC
Ats Arg Leu Lou Pro Pro Ala Lou ***
CCT CCC CAA TCC ACA ACC AAC CTC CCC A..
.(28...... ... ... bp)... ... ... ...
TTT CTC CCC TCA CAA CTC TCT TTC TCt CTC
ACT CAC CCT CCA TTC TCA CCT CCC ACC ACC
CAA CCC ACC ACA TCC CCA CCC TTC CAC CCT
ACC CCC CCC CCA CCC ACC CCC CAC CCC CCC
ATC CAC CtC CCC TCC TCC CCC ACC SCC CAC
Not Clu Vat Arg Trp Cys Ala thr Ser Asp
TCC CTC CTC TCC CtC CCC CCC ACC tCC CCC
Ser Lcu Lau Cys Vat Arg Cly Tbr Ser Ala
CCC ATC TAT GAG CCC CCA AAC GAG CAC CCC
Ala Ile Tyr Clu ALa Cly Lys Cli Hie Cty
CCT CTC CTC ACC ACC ACC TCC CAT CTC ACC
Ala Val Val Avg Arg Ser Scr Hie Val Thr
AAC CTC CCC CC CCC TAC CTC CtC GAG ACC
Ass Val Pro Vat Cly Tyr Lcu Va Cliu Ser
ACC TCC CTC CCC CCC CCA CCA CAC ACC ACT
Ser Cys Val Pro Cly Ala Cly Cli Tbr Ser
AAC ACC CCC CTC CAC ACA TAC TAC CAC TAC
Ly Ser Pro Ls ClIi Arg Tyr Tyr Asp Tyr
ACC CTA CTC CAC AAC ACC CAT CCC AAC ACC
Thr Vat Lou Cli Ass Tbr Asp Cly Lye Tbr
ACC CCC CCC CAT CTC ACC CAC TCC ACC CAC
Ser Arg Ala Asp Vat Thr Cli Trp Arg CIs
CTC ATC TTC CCC CTC CTC AAC CAA CCC CAC
Lci Ile Phe Arg Lou Lou Ass Clu Cly Clo
AAC CAT CTA CTC TtC AAA CAC TCT ACC tCC
Lye Asp Lsu Low Phe Lye Asp Ser Tbr Ser
CCC ATC AAC CCt CTC CTC TCT CAC CCC AAC
Ala Not Lye Cly Lou Lou Cys Asp Pro Ass
CAC ATC CCC CtC CCC TtC CCC CCC CAC CCC
Asp Not Ala Val Ala Phe Arg Arg ClG Arg
CAC CCt CAC CAC CTC CAC CCt CTC ACC CTA
Cl. Ala lCli Cl Vat Asp Ala Val Thr Lou
CAC TAT CCC CCC CAA CAC ACC ACC AAC TCC
lie Tyr Ala Pro ClI Asp Scr Ser Ass Ser
CCC CCC AAC CCC TCC TCC CAC GCC CCt tTC
Arg Cly Lye Arg Ser Cys Sle Ala Cly Pbe
CCC AAC CAC TCt CAC CTC CTC ACA CCA CTC
Pro Lys Asp Cys Asp Val Lou Thr Ala Val
CtC tCt CCA CTC TCC GTC CCC CAC CAC CAC
Los Cys Ala Los Cys Vat Cly Asp ClI Clo
ACC TCC CC CTC CAC AAT CC CCt CAC CTT
Arg Cys Lou Val ClI Ass Ala Cly Asp Vat
CCt CCt CAC CTC ACC TCA GAG CAC TAT CAA
Ala Ala Cl Lou Arg Ser ClI Asp Tyr Clu
CAC ATA CCA CCC CAC CCC CtC ATC CTC CCC
GIn Ie Pro Pro lie Ala Vat Not Vat Arg
CAC CAC CAC AAT AAC AAC CCC TTC AAA ATC
Asp Asp lie Ass Lys Ass Cly Phe Lye Not
CtC CCT CTC CCA CAC AAA ACC ACC TAC CCC
Vat Pro Vat Cly Clu Lye Thr Tbr Tyr Arg
CCC CCA CC CCC CCC CC CCC CCC CCC CCC
Cly Ala Ala Ala Pro Ala Pro Cly Ala Pro
CCC CCC CCC CCC CCC ACA CCt CCC ATC CCC
* .. ... ... *... ... ... .*.. ... ..*. ...*
*. .. .. .. .. .*** *** *.. ..... ... ...
CCt AAC TCT CCC CtA CCC TCC CC? CCC CAT
CCC CCC CTC CTC TCT CAC TCC TAA TCA AAC
CAT AAA AAA AAA
FIG. 3. Nucleotide sequence of the human p97 precursor cDNA and the deduced amino acid sequence. The N-terminal amino acid residues
determined previously by protein sequencing, which are identical to those predicted from the nucleotide sequence, are underlined. The potential
glycosylation sites at amino acids 38, 135, and 515 (open bars) and the membrane anchor region at the C terminus (solid bar) are indicated. One
polyadenylylation signal AATAAA was detected at position 3785, 47 base pairs upstream of a polyadenylylated tract.
to the known N-terminal amino acid sequence of p97 (9),
proving the identity of the cloned cDNA. Furthermore, the
predicted molecular weight of the precursor is 80,196, in good
agreement with the observed molecular weight of the in vitro
translation product.
The amino acid sequence of the p97 precursor comprises
four structural domains. Since residue 20 of the precursor
sequence corresponds to the N terminus of mature p97,
amino acids 1-19 constitute a signal peptide, a conclusion
that is supported by its length and hydrophobic nature.
Amino acids 20-361 and 362-713 comprise homologous
domains of 342 and 352 amino acids. Potential N-glycosyl-
ation sites occur at positions 38 and 135 in the N-terminal
domain and position 515 in the C-terminal domain. Finally,
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we believe that amino acids 714-738, a region of predomi-
nantly uncharged and hydrophobic residues, anchor p97 in
the cell membrane (30) and may extend into the cytoplasm.
The domain structure of p97 is supported by protease
digestion experiments. Digestion of p97 with trypsin, papain
(4), or thrombin produced a glycosylated antigenic fragment
of Mr 40,000. The fragment was purified from a thrombin
digest of p97 that had been metabolically labeled with
[35S]methionine or [35S]cysteine and sequenced as described
(9). Cysteine residues were identified at positions 7 and 17,
and methionine residues were identified at positions 2 and 20.
Identical results were obtained with intact p97 and are in
complete agreement with the N-terminal sequence of p97
predicted from the cDNA sequence. We conclude that the Mr
40,000 protease-resistant fragment corresponds to the N-
terminal domain of p97. We have been unable to isolate the
C-terminal domain of p97, possibly because it is protease
sensitive.
Homology of p97 with Transferrin. A search of the amino
acid sequence library of the Protein Identification Resource
(release 5.0) (31) as described by Wilbur and Lipman (32)
showed that p97 is strikingly homologous to three members
of the transferrin superfamily; human serum transferrin,
human lactotransferrin, and chicken transferrin (37%-39%
homology; Fig. 4). Since human and chicken transferrin show
50% homology to each other, p97 must have diverged from
serum transferrin more than 300 million years ago, when the
mammalian and avian lineages diverged (34). Conservation of
cysteine residues within the domains of p97 and between the
transferrin family members is notable. p97 has 14 cysteine
residues located in homologous positions in each domain.
Human transferrin contains all of these cysteines in homol-
ogous positions in both domains, while human lactotransfer-
rin and chicken transferrin lack only two of these cysteine
residues (in their C-terminal domains). Unlike p97, these
proteins contain 4-7 additional cysteines in their C-terminal
domains, which have no corresponding member in the
N-terminal domain. Human transferrin also contains 2 extra
cysteines unique to its N-terminal domain. The positions of
most of the disulfides in human serum transferrin,
lactotransferrin, and chicken transferrin have been deter-
mined directly (27, 33, 35-38), and one can thus predict the
positions of seven disulfide bonds in each domain of p97.
The amino acid homology between domains of p97 (46%-
achieved by insertion of 7 gaps of 9 residues) is more striking
than that seen in human transferrin (43%-16 gaps, 45
residues) or chicken transferrin (35%-12 gaps, 49 residues).
Given the extensive sequence homology between p97 and
transferrin and the apparently similar folding patterns, based
on the conservation of cysteines, we believe that if the
present low-resolution x-ray structure of transferrin (39) can
be refined it may be possible to deduce the three-dimensional
structure of p97.
Function of p97. Its membership in the transferrin
superfamily, its ability to bind iron (9), and its common
chromosomal localization with transferrin and the transferrin
receptor (10, 11) all support a role for p97 in iron transport.
The iron binding pocket of transferrin is thought to contain
two or three tyrosines, one or two histidines and a single
bicarbonate-binding arginine (33). Conservation of these
amino acids in p97 support its proposed role in iron metab-
olism (Fig. 4). Since p97 is a membrane-bound transferrin-
like molecule and has no homology with the transferrin
receptor (40), its role in cellular iron metabolism may differ
from that provided by circulating serum transferrin and the
cellular transferrin receptor. Expression of the cloned p97
cDNA in eukaryotic cells will allow experimental testing of
its functional properties. Because of its strong homology with
members of the transferrin superfamily and because it was
first isolated from melanoma cells, we propose renaming p97
melanotransferrin.
Obtaining a full-length cDNA for p97 has allowed a detailed
analysis of the primary structure of a human membrane-
bound tumor-associated antigen. p97 should therefore serve
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FIG. 4. Comparison of the predicted amino acid sequence of the p97 precursor and that of human serotransferrin (11,30). Conserved residues
are boxed. Tyrosine, histidine, and arginine residues implicated in iron binding of transferrin are indicated (33).
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as a useful model for this class of proteins and it will be of
interest to see which other tumor-associated differentiation
antigens have structural or functional homology with known
proteins.
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